GSK-backed Liquidia takes a seat at the IPO table, looking for a $57.5M stake to take on United Therapeutics

Liquidia Technologies believes the time is ripe to go public, asking investors to sign on for a $57.5 million IPO designed to get them through a late-stage study of a “new and improved” way to deliver an inhaled drug to treat pulmonary arterial hypertension — and take down United Therapeutics’ standard of care Tyvaso in the process.